Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Study data from M. Mkrtichyan and colleagues update understanding of cancer gene therapy
March 19th, 2008
"The ideal immunological target for cancer vaccine development would meet the criteria of tumor specificity, immuno-genicity and vital dependency of the tumor on the functional activities of the antigenic target so as to avoid antigenic loss by mutation. Given that at face value the brother of regulator of imprinted sites (BORIS) transcription factor meets these criteria, we have developed a mutant variant of this molecule (mBORIS) that lacks tumorigenic ability, while retaining immunogenic epitopes that elicits responses against histologically irrelevant tumor cells," investigators in the United States report. "Here we compared vaccine strategies employing as an...
Source: Vaccine Weekly (2008-03-19)
|
